Sign in

Michael Tung

Research Analyst at Partner Investments

Michael Tung is an Analyst at Partner Investments specializing in technology and consumer sectors, where he focuses on high-growth companies such as Apple, Tesla, and Netflix. Throughout his analyst career, Tung has demonstrated strong performance, achieving a success rate of 62% on investment calls tracked by TipRanks, with an average annualized return of 16%. He began his career with an internship at JP Morgan in 2014, then moved to an equity research associate role at Goldman Sachs before joining Partner Investments as an Analyst in 2018. Holding a Series 7 license and FINRA registration, Tung has received internal recognition for his insightful sector analyses and client-oriented research approach.

Michael Tung's questions to WINDTREE THERAPEUTICS INC /DE/ (WINT) leadership

Question · Q4 2014

Michael Tung of Partner Investments asked for details on clinical indicators from the AEROSURF trial, specifically if there was a difference in the time until babies required a ventilator between the treatment and control groups. He also sought to confirm the timeline for the release of the full data set.

Answer

Chief Development Officer Steven Simonson confirmed that for babies who required intubation, the time to that intervention has been prolonged in the AEROSURF-treated groups as the dose has increased. He assured that this data would be detailed in the final report. CEO John Cooper reiterated the company's expectation to release the full data in the early second quarter of 2015.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts